Panacea Biotec, Bionpharma join hands for generics drugs worth Rs 5,130 crore
New Delhi: Drug firm Panacea Biotec said it has entered into a joint collaboration with the US generic drug maker Bionpharma for development, licence, manufacturing, supply and sales of seven complex generic products.
Panacea Biotec said the joint collaboration is for commercialisation of seven abbreviated new drug applications under development, representing a total estimated market potential of more than USD 800 million (Rs 5,130 crore).
Under the collaboration, Panacea will be responsible for development, filing, registration, manufacturing and supply of these ANDAs, it said in a BSE filing.
Under a previous arrangement, Bionpharma is also the exclusive distributor for companys 2 ANDAs in the US market.
These ANDAs have already been commercialised under a separate exclusive licence and supply agreement.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd